Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Melanoma

Free Subscription Articles published in Nat Med Retrieve available abstracts of 48 articles: HTML format

Single Articles

June 2024
1. LONG GV, Carlino MS, Au-Yeung G, Spillane AJ, et al
   Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF(V600)-mutant resectable melanoma: the randomized phase 2 NeoTrio trial.
   Nat Med. 2024 Jun 21. doi: 10.1038/s41591-024-03077.
   PubMed     Abstract available
   
   
   
2. O'LEARY K
   Neoadjuvant immunotherapy a new standard of care for melanoma.
   Nat Med. 2024 Jun 17. doi: 10.1038/d41591-024-00045.
   PubMed    
   
   
   February 2024
3. BJORK JR, Bolte LA, Maltez Thomas A, Lee KA, et al
   Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
   Nat Med. 2024 Feb 16. doi: 10.1038/s41591-024-02803.
   PubMed     Abstract available
   
   
   January 2024
4. O'LEARY K
   Personalized mRNA vaccine boosts melanoma immunotherapy.
   Nat Med. 2024 Jan 25. doi: 10.1038/d41591-024-00006.
   PubMed    
   
   
   
5. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
   Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
   Nat Med. 2024 Jan 4. doi: 10.1038/s41591-023-02775.
   PubMed    
   
   
   November 2023
6. FRATERMAN I, Reijers ILM, Dimitriadis P, Broeks A, et al
   Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
   Nat Med. 2023 Nov 13. doi: 10.1038/s41591-023-02631.
   PubMed     Abstract available
   
   
   
7. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
   Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
   Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02650.
   PubMed    
   
   
   
8. KIRKWOOD JM, Del Vecchio M, Weber J, Hoeller C, et al
   Publisher Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
   Nat Med. 2023 Nov 3. doi: 10.1038/s41591-023-02661.
   PubMed    
   
   
   October 2023
9. KIRKWOOD J, Del Vecchio M, Weber J, Hoeller C, et al
   Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
   Nat Med. 2023 Oct 16. doi: 10.1038/s41591-023-02583.
   PubMed     Abstract available
   
   
   August 2023
10. VANDERWALDE A, Bellasea SL, Kendra KL, Khushalani NI, et al
    Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
    Nat Med. 2023 Aug 17. doi: 10.1038/s41591-023-02498.
    PubMed     Abstract available
    
    
    
11. CARVALHO T
    Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial.
    Nat Med. 2023 Aug 16. doi: 10.1038/d41591-023-00072.
    PubMed    
    
    
    
12. BARATA C, Rotemberg V, Codella NCF, Tschandl P, et al
    A reinforcement learning model for AI-based decision support in skin cancer.
    Nat Med. 2023;29:1941-1946.
    PubMed     Abstract available
    
    
    July 2023
13. ROUTY B, Lenehan JG, Miller WH Jr, Jamal R, et al
    Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.
    Nat Med. 2023 Jul 6. doi: 10.1038/s41591-023-02453.
    PubMed     Abstract available
    
    
    
14. BRASTIANOS PK, Kim AE, Giobbie-Hurder A, Lee EQ, et al
    Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
    Nat Med. 2023;29:1728-1737.
    PubMed     Abstract available
    
    
    May 2023
15. GARBE C, Dummer R, Amaral T, Amaria RN, et al
    Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
    Nat Med. 2023 May 16. doi: 10.1038/s41591-023-02336.
    PubMed    
    
    
    April 2023
16. LIU S, Dharanipragada P, Lomeli SH, Wang Y, et al
    Multi-organ landscape of therapy-resistant melanoma.
    Nat Med. 2023 Apr 27. doi: 10.1038/s41591-023-02304.
    PubMed     Abstract available
    
    
    
17. GLITZA OLIVA IC, Ferguson SD, Bassett R Jr, Foster AP, et al
    Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
    Nat Med. 2023;29:898-905.
    PubMed     Abstract available
    
    
    March 2023
18. O'LEARY K
    Earlier appears better for immunotherapy in melanoma.
    Nat Med. 2023 Mar 16. doi: 10.1038/d41591-023-00028.
    PubMed    
    
    
    
19. CASCONE T, Leung CH, Weissferdt A, Pataer A, et al
    Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
    Nat Med. 2023 Mar 16. doi: 10.1038/s41591-022-02189.
    PubMed     Abstract available
    
    
    February 2023
20. SOLIMAN H, Hogue D, Han H, Mooney B, et al
    Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial.
    Nat Med. 2023;29:450-457.
    PubMed     Abstract available
    
    
    
21. TIAN J, Chen JH, Chao SX, Pelka K, et al
    Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial.
    Nat Med. 2023;29:458-466.
    PubMed     Abstract available
    
    
    
22. NIKNAFS N, Balan A, Cherry C, Hummelink K, et al
    Persistent mutation burden drives sustained anti-tumor immune responses.
    Nat Med. 2023;29:440-449.
    PubMed     Abstract available
    
    
    December 2022
23. TAYLOR CA, Watson RA, Tong O, Ye W, et al
    IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
    Nat Med. 2022 Dec 16. doi: 10.1038/s41591-022-02095.
    PubMed     Abstract available
    
    
    November 2022
24. SIMPSON RC, Shanahan ER, Batten M, Reijers ILM, et al
    Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
    Nat Med. 2022;28:2344-2352.
    PubMed     Abstract available
    
    
    October 2022
25. CARVAJAL RD, Butler MO, Shoushtari AN, Hassel JC, et al
    Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
    Nat Med. 2022 Oct 13. pii: 10.1038/s41591-022-02015.
    PubMed     Abstract available
    
    
    July 2022
26. ZHANG Y, Trang V, Palmer DC, Kishton RJ, et al
    A T cell resilience model associated with response to immunotherapy in multiple tumor types.
    Nat Med. 2022;28:1421-1431.
    PubMed     Abstract available
    
    
    June 2022
27. REIJERS ILM, Menzies AM, van Akkooi ACJ, Versluis JM, et al
    Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
    Nat Med. 2022 Jun 5. pii: 10.1038/s41591-022-01851.
    PubMed     Abstract available
    
    
    April 2022
28. MONTEIRO C, Miarka L, Perea-Garcia M, Priego N, et al
    Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
    Nat Med. 2022;28:752-765.
    PubMed     Abstract available
    
    
    March 2022
29. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2022 Mar 8. pii: 10.1038/s41591-022-01771.
    PubMed    
    
    
    February 2022
30. MCCULLOCH JA, Davar D, Rodrigues RR, Badger JH, et al
    Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
    Nat Med. 2022 Feb 28. pii: 10.1038/s41591-022-01698.
    PubMed     Abstract available
    
    
    
31. LEE KA, Thomas AM, Bolte LA, Bjork JR, et al
    Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
    Nat Med. 2022 Feb 28. pii: 10.1038/s41591-022-01695.
    PubMed     Abstract available
    
    
    January 2022
32. LOZANO AX, Chaudhuri AA, Nene A, Bacchiocchi A, et al
    T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
    Nat Med. 2022 Jan 13. pii: 10.1038/s41591-021-01623.
    PubMed     Abstract available
    
    
    December 2021
33. KJELDSEN JW, Lorentzen CL, Martinenaite E, Ellebaek E, et al
    A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
    Nat Med. 2021;27:2212-2223.
    PubMed     Abstract available
    
    
    
34. O'LEARY K
    FMT for patients with cancer.
    Nat Med. 2021;27:2057.
    PubMed    
    
    
    October 2021
35. DUMMER R, Gyorki DE, Hyngstrom J, Berger AC, et al
    Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial.
    Nat Med. 2021 Oct 4. pii: 10.1038/s41591-021-01510.
    PubMed     Abstract available
    
    
    August 2021
36. ANDREWS MC, Duong CPM, Gopalakrishnan V, Iebba V, et al
    Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
    Nat Med. 2021;27:1432-1441.
    PubMed     Abstract available
    
    
    May 2021
37. LIU D, Lin JR, Robitschek EJ, Kasumova GG, et al
    Evolution of delayed resistance to immunotherapy in a melanoma responder.
    Nat Med. 2021 May 3. pii: 10.1038/s41591-021-01331.
    PubMed     Abstract available
    
    
    February 2021
38. MENZIES AM, Amaria RN, Rozeman EA, Huang AC, et al
    Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01188.
    PubMed     Abstract available
    
    
    
39. ROZEMAN EA, Hoefsmit EP, Reijers ILM, Saw RPM, et al
    Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-020-01211.
    PubMed     Abstract available
    
    
    January 2021
40. PEREZ-GUIJARRO E, Yang HH, Araya RE, El Meskini R, et al
    Author Correction: Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
    Nat Med. 2021 Jan 29. pii: 10.1038/s41591-021-01252.
    PubMed    
    
    
    
41. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    PubMed     Abstract available
    
    
    
42. STOWER H
    Microbiome transplant-induced response to immunotherapy.
    Nat Med. 2021;27:21.
    PubMed    
    
    
    
43. YU J, Green MD, Li S, Sun Y, et al
    Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.
    Nat Med. 2021;27:152-164.
    PubMed     Abstract available
    
    
    October 2020
44. CEREZO-WALLIS D, Contreras-Alcalde M, Troule K, Catena X, et al
    Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
    Nat Med. 2020 Oct 19. pii: 10.1038/s41591-020-1073.
    PubMed     Abstract available
    
    
    
45. DUMMER R, Lebbe C, Atkinson V, Mandala M, et al
    Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
    Nat Med. 2020;26:1557-1563.
    PubMed     Abstract available
    
    
    
46. ALGAZI AP, Othus M, Daud AI, Lo RS, et al
    Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
    Nat Med. 2020;26:1564-1568.
    PubMed     Abstract available
    
    
    
47. RYLL B
    From good to great: what patients can do for your medical research.
    Nat Med. 2020;26:1508.
    PubMed    
    
    
    July 2020
48. ALLEN BM, Hiam KJ, Burnett CE, Venida A, et al
    Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.
    Nat Med. 2020;26:1125-1134.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.